Table of Contents
Shanghai Jiahui International Hospital, an internationally renowned medical institution, was the first to receive CAR-T cell therapy from Fucaso (Equecabtagene Autoleucel). Foreign myeloma patient was discharged within two weeks of completing treatment.
Patient Profile and CAR-T Treatment Journey
The patient, from New Zealand, was diagnosed with multiple myeloma in 2008. Despite receiving multiple treatments, including chemotherapy, immunotherapy, targeted therapy, and autologous stem cell transplantation, he unfortunately relapsed again in 2022 with severe pain and bone damage.
After consultation with Director Li Hua and Dr. Zhou Lili of the blood team of Jiahui International Cancer Center, the patient decided to carry out CAR-T cell therapy at Jiahui International Hospital. The entire treatment process went smoothly and the patient was discharged within two weeks of treatment.
Global Impact of Fucaso CAR-T Therapy
Jiahui International Hospital has the software and hardware conditions that are in line with the international level, and the comprehensive treatment of tumors, and many overseas patients with multiple myeloma have gone to Jiahui International Hospital for Fucaso treatment.
Since its launch in China, IASO has reached strategic cooperation with a number of domestic and international hospitals to jointly build an international CAR-T diagnosis and treatment center serving patients around the world. Internationally renowned medical institutions have abundant medical resources and an extensive channel network, and their participation will accelerate the benefits of Fucaso to more overseas patients.
Final Words
At present, a number of overseas patients have benefited, demonstrating the R&D strength and development potential of China’s innovative drugs. IASO Bio sciences will continue to focus on international synchronous and leading treatment concepts, drugs and technologies, promote the long-term sustainable development of the CAR-T international diagnosis and treatment platform, and bring hope of cure to patients with multiple myeloma at home and abroad!
Related Article
